The stock is in a pronounced downtrend, with a 1-year price change of -24.18%, significantly underperforming the SPY's +22.86% gain. As of the latest close at $77.41, the price is trading near the lower end of its 52-week range, approximately 35% above its 52-week low of $68.84 but only 64% of the way towards its 52-week high of $120.05, indicating the stock is in a deep correction and presenting a potential value opportunity, albeit with significant technical damage. Recent momentum shows a short-term rebound, with a 1-month price change of +8.13%, which contrasts sharply with the negative 3-month change of -1.10% and the severe 6-month decline of -16.57%. This divergence suggests the stock may be attempting to find a bottom after its steep decline, though the 1-month rally has occurred on relatively weak volume, averaging around 1.3 million shares, and the stock's low beta of 0.32 indicates it has been far less volatile than the broader market during this turbulent period.

Key technical support is clearly defined at the 52-week low of $68.84, while resistance is at the recent high near $102.23 from January 2026. A sustained break above the $80-$85 zone, which has acted as resistance in recent months, would signal the beginning of a more meaningful recovery. Conversely, a decisive break below the $68.84 support would open the door for further downside, potentially extending the -44.8% maximum drawdown experienced over the observed period. The stock's low beta of 0.32 suggests it has exhibited only about one-third of the market's volatility, which is unusual for a stock in a sharp downtrend and may indicate it is being treated as a defensive holding despite its price action.

Revenue growth has decelerated, with the most recent quarterly revenue of $2.62 billion representing a -10.19% year-over-year decline, a stark reversal from the stronger growth seen in prior quarters. The revenue mix shows a heavy reliance on Cost Reimbursable Contracts at $1.52 billion, with Fixed-price and Time-and-materials contracts contributing $521 million and $584 million respectively, indicating potential margin pressure as the revenue base contracts. This negative growth trajectory raises concerns about the company's ability to secure and ramp up new contracts to offset legacy program declines, directly impacting the investment thesis.

The company remains profitable, posting net income of $200 million in the latest quarter, translating to a net margin of 7.6%. However, profitability has compressed; gross margin for the quarter was 51.95%, but the key metrics data shows a trailing twelve-month gross margin of 20.9% and an operating margin of 9.75%, indicating significant variance and potential cost pressures or mix shifts on a TTM basis. The quarterly net income of $200 million and diluted EPS of $1.64 show the company is still generating earnings, but the margin compression trend from higher-margin periods is a key watch item for investors.

The balance sheet carries significant leverage with a debt-to-equity ratio of 3.73, which is high and indicates aggressive use of debt financing. However, liquidity appears adequate with a current ratio of 1.78. The company is a robust generator of free cash flow, with TTM FCF of $933 million, providing ample coverage for its dividend (payout ratio of 32.4% and yield of 2.87%) and share repurchases. The return on equity is exceptionally high at 77.0%, but this is heavily amplified by the high financial leverage, which also increases financial risk. The strong FCF generation is a positive offset to the elevated debt levels.